PainReform (PRFX) has released an update.
PainReform Ltd. has completed the enrollment phase for its pivotal Phase 3 clinical trial of PRF-110, targeting post-operative pain, with 428 patients across the U.S. This marks a significant step towards offering a non-opioid pain management solution, with the drug’s top-line results expected in the latter half of 2024. PRF-110 utilizes a patented extended-release formulation of ropivacaine aimed at providing prolonged pain relief and reducing opioid dependency in post-surgical care.
For further insights into PRFX stock, check out TipRanks’ Stock Analysis page.
